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Abstract
Botulinum neurotoxins are highly toxic, and bind two receptors to achieve their high affinity and
specificity for neurons. Here we present the first structure of a botulinum neurotoxin bound to
both its receptors. We determine the 2.3 Å structure of a ternary complex of botulinum neurotoxin
type B bound to both its protein receptor Synaptotagmin II and its ganglioside receptor GD1a. We
show that there is no direct contact between the two receptors, and that the binding affinity
towards Synaptotagmin II is not influenced by the presence of GD1a. The interactions of
botulinum neurotoxin type B with the sialic acid 5 moiety of GD1a are important for the
ganglioside selectivity. The structure demonstrates that the protein receptor and the ganglioside
receptor occupy nearby but separate binding sites, thus providing two independent anchoring
points.
Introduction
Botulinum neurotoxins (BoNT) are the most toxic substances known, with an LD50 value of
approximately 1 ng/kg1. Seven distinct serotypes of BoNTs (A–G) exist2,3. Due to their
extreme toxicity, they are one of the top potential bioterrorism agents. However, members of
botulinum neurotoxins (BoNT/A and B) are also extensively used therapeutically to treat
numerous medical conditions, such as cervical dystonia, cerebral palsy, strabismus,
hemifacial spasm and myofascial pain, as well as for cosmetic purposes4–6.
These toxins are composed of three domains: the Light Chain (LC), the translocation
domain (HN) and the binding domain (HC). The LC (~ 50 kDa), is a Zn-protease responsible
for the cleavage of the SNARE (soluble NSF attachment protein receptor) proteins targeted
by the toxin. SNARE proteins are central in synaptic vesicle exocytosis; cleavage of
SNARE proteins by BoNTs inhibits acetylcholine release at the neuromuscular junctions7.
HN (~ 50 kDa) is responsible for transport of the LC over the endosomal membrane. HC
(~50 kDa) binds to receptors on nerve terminals2,8,9. HC is further divided into HCN and
HCC, with HCN being highly conserved and HCC diverse in sequence. The receptors bound
by HCC and the final protein being targeted by the LC varies between serotypes. In general,
BoNTs achieve their high affinity and specificity for neurons by binding two receptors;
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gangliosides and one of the two synaptic vesicle proteins, synaptotagmin (Syt) or synaptic
vesicle protein 2 (SV2). BoNT/A, D and E use SV2 as their protein receptor10–13, BoNT/F
might also utilize SV214,15, although this has not been functionally confirmed13,16. BoNT/B
and BoNT/G, bind Syt, both the Syt-I and Syt–II isoforms, as their protein receptors18–24. In
addition, the protein receptors of a BoNT subtype, type DC, are Syt-I and Syt-II17.
Gangliosides bind in a ganglioside binding site (GBS), conserved in all serotypes except C
and D, consisting of a SXWY motif14,15,25–30. BoNT/C and D have in the same site an
analogous GBS31–33. Independent of which receptor the BoNT bind, the end result is
similar; cleavage of SNARE proteins by the LC leading to muscle paralysis8.
Structures showing BoNT binding to either its protein receptor or gangliosides alone have
been reported, including BoNT/B in complex with its protein receptor, synaptotagmin II
(Syt-II)19,22, BoNT/A with ganglioside GT1b28, and BoNT/F with ganglioside GD1a34.
Structures are also available for BoNT/B, C, and D bound to smaller sugars25,31,33,35.
However, how BoNTs bind to both protein receptors and gangliosides simultaneously
remains to be established at the structural level. Furthermore, no structure of BoNT/B bound
to a complex ganglioside has previously been determined.
Here, we solve the structure of the first ternary complex of a BoNT bound to both its protein
receptor and ganglioside. We determine the 2.3 Å structure of BoNT/B bound to Syt-II and
the ganglioside GD1a. We show that the binding of GD1a does not influence the toxins
affinity for Syt-II. Our results show that the two receptor binding sites are independent of
each other.
Results
Overall structure of the complex
In a similar approach as previously reported, BoNT/B-HC was constructed and purified as a
fusion construct together with Syt-II22. This recombinant protein was then pre-incubated
with GD1a, a major brain ganglioside known to bind BoNT/B36, devoid of the ceramide
part. Subsequent co-crystallization experiments yielded crystals that diffracted to 2.3 Å
(Table 1). The structure was solved using molecular replacement. Residues 862–1291 of
BoNT/B-HC were visible in the electron density, with the exception of two flexible loops
between residues 1151–1159 and 1245–1252. Well-defined electron density became visible
during refinement, accounting for both the fused Syt-II toxin binding region (residues 45–
59), and the entire GD1a ganglioside sugar (Fig. 1a). The remainder of the fused Syt-II was
disordered and not visible in the electron density. The asymmetric unit contained two BoNT/
B molecules, which were virtually identical (r.m.s.d. of 0.4 Å).
The structure shows that Syt-II is bound in a hydrophobic crevice on the tip of BoNT/B (Fig.
1a). The overall structure obtained in the ternary complex is virtually identical to the
previously reported BoNT/B•Syt-II complex structures19,22, demonstrating that
simultaneous ganglioside binding does not cause any significant structure changes in BoNT/
B.
Ganglioside binding to BoNT/B
This is the first structure of BoNT/B in complex with a complex ganglioside. The
ganglioside binding site (GBS) on BoNT/B has been previously mapped, mainly through
mutagenesis studies, and contains a conserved SXWY motif26. The ternary complex
structure revealed that GD1a indeed binds to this established GBS (Fig. 1 and 2). Four
subunits of GD1a (Sialic acid (Sia5), Galactose (Gal4), N-acetylglucosamine (GalNAc3)
and Sia6) make contacts to the GBS of BoNT/B (Fig. 1b). Sia5 forms hydrogen bonds to
N1273, N1105, G1277 and Y1263, Gal4 to I1240, H1241, S1260 and E1190. GalNAc3 and
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Sia6 form one hydrogen bond each, to E1190 and W1262 respectively. W1262 is
furthermore forming crucial aromatic stacking interactions with Gal4. The remaining two
subunits of GD1a, Glc1 and Gal2, do not interact with the GBS, but are still visible in the
electron density due to the crystal packing to the second monomer in the asymmetric unit
(Fig. 3). These crystal contacts are not biologically relevant; BoNT/B has previously been
shown to have a single GBS26. Key residues in the GBS mapped by previous mutagenesis
studies, are highlighted with a star in the figure (Fig. 1b)26.
We next compared the structure of BoNT/B•GD1a with the previously reported structures of
BoNT/A•GT1b28 and BoNT/F•GD1a34 (Fig. 2). We found that there are significant
differences in the position of most sugar moieties (Fig. 2a–d). However, the position of Gal4
is fairly conserved in all three structures. Interestingly GD1a has shifted one unit when
compared with the previously determined structure of BoNT/B with bound sialyllactose25
(Fig. 2e,f). This shift could indicate plasticity in the binding site, with different sugars being
able to occupy the binding sites in different binding registers. Alternatively, the use of a
partial mimic of the ganglioside or soaking could have influenced the position25.
BoNT/B ternary complex
Importantly, the structure of BoNT/B in the ternary complex, does not undergo any
significant conformational changes as compared to apo BoNT/B and the BoNT/B•Syt-II
complex19,22,25 with an HCC r.m.s.d. of 0.4 and 0.3 Å, respectively. Binding of the receptors
induces only minor adjustments of the positions of side chains in the binding sites. For
instance, W1262 moves slightly in the direction of Gal4. Gal2 and Glc1 are located between
the membrane and the toxin, and are likely flexible. However, even allowing these moieties
to be flexible, sterical and distance restraints likely prevents the ganglioside to reach the
protein receptor in BoNT/B for a direct interaction. The closest distance between GD1a and
Syt-II is 15 Å. E1190 interacts with GD1a and E1191 interacts with Syt-II, this is the closest
connection between the binding sites. This result further establishes that the high binding
affinity mainly is the product of two independent anchoring points, with no direct
interactions between the binding sites or the receptors (Fig. 1 and 4). Furthermore, the toxins
binding to the receptors impose sterical restrains on the interaction with the membrane (Fig
4).
GD1a does not influence the affinity for Syt-II
To further confirm the lack of allosteric effects between the dual receptors, we measured the
binding affinity of rat Syt-II peptide (residue 40–60) to BoNT/B-HC, without and with a pre-
incubation with GD1a oligosaccharide. Isothermal titration calorimetry (ITC) gave a KD of
0.14 ± 0.05 µM and 0.18 ± 0.06 µM, respectively (Fig. 5). The presence of GD1a did thus
not significantly affect the binding affinity between Syt-II and BoNT/B, further indicating
that there is no allosteric contribution in the binding of Syt-II and GD1a.
Discussion
The dual receptor concept for BoNT family toxins was proposed 27 years ago37. The ternary
structure, of BoNT/B bound to both Syt-II and GD1a concurrently, presented here, now
proves the dual receptor model at the structural level. The structure demonstrates that the
binding sites are separate and there are only minor changes in the structure upon binding of
the receptors. There is no allosteric contribution in the binding of Syt-II and GD1a to BoNT/
B. Due to the high sequence similarity between the recognition domains of Syt-I and Syt-II,
it is likely that these receptors bind the toxin in a very similar way.
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This is the first structure reported of BoNT/B bound to a complex ganglioside. Previous
experiments have shown that GT1b and GD1a support BoNT/B binding, but that GD1b and
GM1 bind substantially weaker21,36,38. The structure presented here reveals the structural
basis for this selectivity that arises from the interactions of Sia5. The Sia5 moiety is strongly
bound to BoNT/B with key interactions for the overall binding of the ganglioside. Both
GT1b and GD1a have a Sia5 moiety, whereas GD1b and GM1 do not, explaining the
differences in affinity. Furthermore, K1265 and R1269, close to W1262, are well positioned
to interact with the second sialic acid moiety present in GT1b (but not in GD1a), likely
contributing to GT1b having even higher affinity than GD1a for binding BoNT/B25,36.
The detailed description of dual receptor binding to BoNT/B can be used to develop toxin
countermeasures targeting both sites simultaneous, thus benefitting from the high affinity
achieved by binding multiple sites, as naturally occurring in the BoNTs.
Methods
Constructs and peptides
The cDNA encoding BoNT/B-HC (residues 857 – 1291, GenBank: AB232927) was
synthesized by GeneArt (Regensburg, Germany), with codon optimized for E.coli
expression. The cDNA encoding mouse Syt II was generously provided by M. Fukuda
(Ibaraki, Japan). The BoNT/B-HC•Syt-II fusion construct was built by fusing BoNT/B-HC
directly to the N-terminus of Syt II (residues 8–61) by overlapping PCR, and subcloned into
pET-28a vector at Nhe/XhoI site. The following additional residues from pET28 vectors
were also expressed in the fusion protein:
N-terminus before BoNT/B-HC: MGSSHHHHHHSSGLVPRGSHMASM;
C-terminus after Syt II: VLEHHHHHH.
Peptide corresponding to the toxin-binding site in rat Syt-II (residue 40–60) was synthesized
(>95% purity) by JPT Peptide Technologies Gmgh (Germany).
Protein expression and purification
Double His-6 tagged BoNT/B-HC – Syt-II was expressed in Escherichia coli (BL21 strain).
The cells were grown in terrific broth medium containing 50 µg/mL kanamycin, and grown
in 2 L flasks at 37°C, pH 7.0, with addition of air to mix the medium and maintain an excess
of oxygen, to an OD600 of ~1.5. The temperature was then lowered to 20°C, and expression
induced by the addition of IPTG with a final concentration of 1mM. After over-night
induction the cells were harvested and frozen in −80°C. For protein purification, the pelleted
cells were thawed, resuspended to an OD600 of ~100 in 50 mM KPi pH 7.5, 300 mM NaCl
and 10% glycerol. Lysation was performed by passing the cell suspension 2 times through
an Emulsiflex-C3 (Avestin, Germany) at 20 kPsi. Unlysed cells and cell debri was spun
down via ulta-centrifugation at 4°C, 267k ×g for 60 min. The supernatant was collected,
imidazole, pH 7.8, was added to a final concentration of 12 mM, and incubated with 0.5 mL
Ni-NTA per 10 mL supernatant at 4°C for 60 min, rotating. The material was then packed in
a disposable 10 mL column (BioRad), washed 20 column volumes with wash buffer (50 mM
Hepes, pH 7.8, 300 mM NaCl and 45 mM imidazole, pH 7.8). The protein was then eluted
using wash buffer supplemented with 500 mM imidazole, pH 7.8. Purification was then
finished by running the protein over a Superdex 200 10/300GL size exclusion column, pre-
equilibrated with 20 mM Hepes pH 7.0, 150 mM NaCl. The peak fractions were pooled and
concentrated to 5.0 mg/mL, using a 30 kDa molecular weight cut off spin concentrator
(Vivaspin). Glycerol was then added to a final concentration of 10%, and the protein was
subsequently flash frozen in liquid nitrogen and stored at −80°C. Expression and
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purification of BoNT/B-HC for isothermal titration calorimetry (ITC) experiments was
performed in the same way as BoNT/B-HC – SytII, with the exception that BoNT/B-HC was
not frozen, and the final buffer in the size exclusion chromatography was 20 mM KPi pH
7.0, 150 mM NaCl.
Crystallization and structure determination
Purified protein was thawed, GD1a oligosaccharide (Elicityl, France) was added to a final
concentration of 2.5 mM, and was subsequently crystallized using the vapor diffusion
technique. Diffraction quality crystals grew from a solution containing 0.2 M MgCl2, 0.1 M
Hepes pH 7.0 – 7.2 and 20–24% PEG 6000. Crystals appeared between 8–12 weeks. For
cryo protection, they were washed in mother liquor supplemented with 40% PEG 6000, and
subsequently flash frozen in liquid nitrogen. Diffraction data was collected at 0.918 Å at
beamline 14.1, BESSY, Berlin. The crystals diffracted to 2.3 Å, and were in space group
P21. Data processing and reduction were carried out using XDS39 and programs from the
CCP4 suite40. Relevant statistics are shown in Table 1. The structure was solved via
molecular replacement, using the previously solved structure of BoNT/B as a search model
(PDB code: 2NM1). A few cycles of refinement in Refmac5 and Phenix.refine41,42,
interspersed with model building using Coot43, were needed to build the full model and its
ligands. The final structure contains residues 862–1291, with the exception of two loops,
1152–1158 and 1246–1252 that had ambiguous electron density. At the N-terminus, 6
residues of BoNT/B are missing (MNSEIL), as well as the N-terminal tag. The Syt-II
binding domain, residues 45–59, has well defined electron density, leaving residues 1–44 of
Syt-II (which acts as a linker in this construct) flexible. Furthermore, the entire GD1a
molecule is visible in the electron density. The highest resolution data, to 2.3 Å, had a twin
fraction of ca 35 %, as analyzed via phenix.xtriage42. The structure was therefore refined
using twin refinement. Another crystal form, in space group C2, diffracted to 2.6 Å and did
not have twinning. The structure was also solved with this data, which was not twinned, and
used for comparison with the higher resolution structure obtained from the twinned data.
Final Rwork/Rfree of the untwinned data was 21.5 / 26.1 %. No substantial differences were
observed between the two structures, and since the twinned data with higher resolution gave
better final electron density, we choose to use that data for the final model building.
Isothermal titration calorimetry
Binding of synaptotagmin to BoNT/B-HC was measured via isothermal titration calorimetry
on a ITC200 (GE Healthcare) at 25°C and 1000 rpm. 200 µL of BoNT/B-HC (typically
concentrated to 10–25 µM, in 20 mM KPi pH 7.5, 150 mM NaCl) was added to the cell. In
the case of GD1a oligosaccharide addition, 0.25 mM was added to the protein and incubated
for 10 min on ice before adding the protein to the cell. Binding was measured upon addition
of Syt-II peptide in a stepwise manner, typically 16 injections of 2.6 µL each, at a
concentration of 10–15 times the protein concentration in the cell. The first titration was 0.5
µL, and was subsequently deleted in the data analysis. The analysis was performed using the
software provided by the manufacturer.
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Figure 1. Dual receptor binding to BoNT/B
(a) Overall view of BoNT/B (gray) with GD1a (green) and mouse Syt-II (orange) bound.
Lower panel shows a close up view on the GD1a and Syt-II binding sites, with the GD1a
moieties and the Syt-II residues, interacting with BoNT/B, shown as sticks. Phenylalanine
54 is indicated, this position is a leucine in human Syt-II that has a drastically lower affinity
to BoNT/B than mouse Syt-II17,44. (b) Schematic overview of possible hydrogen bonds
between GD1a and BoNT/B (red dashed lines) and an internal hydrogen bond (blue dashed
line). The hydrogen bond distance is shown for each bond (Å). Red stars show residues that
previously, via mutagenesis, have been shown to be important for ganglioside binding26. In
GD1a, a ceramide is present at the R position, the GD1a oligosaccharide used here has a
hydrogen in this position. (c) Stereo view of the bound GD1a, with its electron density (2FO-
FC map contoured at 1.5σ) in blue, and the possible hydrogen bonds to BoNT/B residues as
dashed lines.
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Figure 2. Comparison of the ganglioside binding to BoNT/B, BoNT/A and BoNT/F
The residues corresponding to W1262 and H1241 are shown in all structures. In the
schematic panels (a, c & e) the individual sugar moieties are depicted as follows; triangles =
Sia, rectangles = Gal, circle = GalNAc, star = Glc. In all panels BoNT/B with GD1a bound
is depicted in gray and dark gray, respectively. The right hand panels (b, d & f) are stereo
figures of the GBS. (a–b) Comparison to BoNT/A with GT1b (green, PDB code: 2VU9). (c–
d) Comparison to BoNT/F and its bound GD1a (magenta, PDB code: 3RSJ). (e–f)
Comparison to BoNT/B and its bound sialyllactose (cyan, PDB code: 1F31).
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Figure 3. The asymmetric unit
The asymmetric unit containing two molecules of BoNT/B (gray), with the bound
recognition domain of Syt-II (orange) and GD1a (green). The second copy of each molecule
is colored in beige. All residues that interact with GD1a are shown as sticks. Crystal contacts
are formed between the two BoNT/B protomers (gray and beige) in the asymmetric unit via
the bound GD1a molecules. GD1a is bound to the GBS, as described in Fig. 1. The crystal
contacts are formed by Glc1, Gal2 and Sia6. The green GD1a forms 3 hydrogen bonds, to
S984, N1025 and L1022. The beige GD1a forms 5 hydrogen bonds, to S984, F986, N1025
and T1026. These interactions are not biologically relevant since BoNT/B has been shown
to have a single GBS26.
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Figure 4. Model of BoNT binding to the neuronal membrane
The HC (green), with its bound Syt-II (brown) and GD1a (blue), is from this study, while the
HN (purple) and LC (red) is superimposed using the structure of the entire BoNT/B (PDB
code: 2NP0). The protein orientation is restricted by the binding of the two receptors. The
structure presented here supports the entry of the translocation domain into the membrane
with the end of the long helixes first22,28. The regions linking both the protein receptor and
ganglioside receptor to the membrane does allow for a certain degree of flexibility of the
toxins orientation.
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Figure 5. ITC titrations of Syt-II to BoNT/B
Representative ITC titrations of Syt-II to BoNT/B, without (a) and with (b) pre-incubation
of 75 µM GD1a. (a) KD = 0.14 ± 0.05 µM (b) KD = 0.18 ± 0.06 µM. The error is the
standard deviation on at least two independent measurements. The baseline above zero in (b)
is due to a slight buffer mismatch, and does not influence the calculated values.
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Table 1
Data collection and refinement statistics
Data collection
Space group P21
Cell dimensions
    a, b, c (Å) 47.2, 158.2, 75.2
    α, β, γ (°) 90.0, 108.4, 90.0
Resolution (Å) 44.7 – 2.3 (2.42-2.3)
Rmeas (%) 14.1 (79.3)
I/σ (I) 10.9 (2.3)
Completeness (%) 99.7 (98.5)
Redundancy 4.3
Refinement
Resolution 44.7 – 2.3
No. unique reflections 50612
Rwork/Rfree 15.5 / 18.9
No. atoms
  Protein 7161
  Syt-II ligand 284
  GD1a ligand 176
  Water 264
B-factors
  Protein 25.0
  Syt-II Ligand 31.2
  GD1a ligand 26.9
  Water 21.1
R.m.s. deviations
  Bond lengths (Å) 0.008
  Bond angles (°) 1.28
The data was collected from one crystal. Values in parenthesis are for the highest-resolution shell
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